Godavari Drugs

{
  "main_header": {
    "sid": 765253,
    "name": "Godavari Drugs",
    "stock_name": "Godavari Drugs",
    "full_name": "Godavari Drugs Ltd",
    "name_url": "stocks-analysis/godavari-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "88.10",
    "chg": -1.27,
    "chgp": "-1.42%",
    "dir": -1,
    "prev_price": "89.37",
    "mcapval": "67.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530317,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE362C01012",
    "curr_date": "Feb 11",
    "curr_time": "",
    "bse_nse_vol": "1.07 k",
    "exc_status": "Active",
    "traded_date": "Feb 11, 2026",
    "traded_date_str": "2026 02 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/godavari-drugs-765253-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Godavari Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-godavari-drugs-ltd-latest-results-good-or-bad-3833392",
        "imagepath": "",
        "date": "2026-02-11 19:30:17",
        "description": "The latest financial results for Godavari Drugs Ltd for the quarter ending September 2025 reflect a complex operational landscape. The company reported net sales of ₹26.65 crores, which represents a sequential growth of 11.93% compared to the previous quarter's ₹23.81 crores. However, year-on-year growth is modest at just 2.15%, indicating that while there is some recovery in sales, it is not keeping pace with broader market expectations.\n\nIn terms of profitability, net profit for the quarter was ₹1.00 crore, reflecting a decline of 3.85% from the previous quarter and an 8.26% decrease year-on-year. This decline in profit is concerning, especially as it coincides with a significant drop in operating margins, which fell to 7.47%, the lowest level recorded in the past seven quarters. This margin compression is indicative of ongoing challenges, including rising input costs and pricing pressures in the active p..."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-strong-sell-3830550",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/GodavariDrugsLt_mojoScore_3830550.png",
        "date": "2026-02-10 10:10:07",
        "description": "Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-strong-sell-3811166",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GodavariDrugsLt_mojoScore_3811166.png",
        "date": "2026-01-30 10:10:03",
        "description": "Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-strong-sell-3793980",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GodavariDrugsLt_mojoScore_3793980.png",
        "date": "2026-01-19 10:10:32",
        "description": "Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-strong-sell-3784488",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/GodavariDrugsLt_mojoScore_3784488.png",
        "date": "2026-01-07 10:10:23",
        "description": "Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics presented here are based on the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and prospects."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-strong-sell-3769702",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GodavariDrugsLt_mojoScore_3769702.png",
        "date": "2025-12-25 15:12:53",
        "description": "Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and prospects."
      },
      {
        "title": "Godavari Drugs Stock Hits 52-Week Low at Rs.69.7 Amidst Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-falls-to-52-week-low-of-rs697-amidst-continued-weakness-3753811",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GodavariDrugs_priceRelatedfactors_3753811.png",
        "date": "2025-12-09 11:23:32",
        "description": "Godavari Drugs has reached a new 52-week low of Rs.69.7, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year."
      },
      {
        "title": "Godavari Drugs Stock Falls to 52-Week Low of Rs.70.31 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-stock-falls-to-52-week-low-of-rs7031-amid-continued-weak-performance-3751223",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GodavariDrugs_priceRelatedfactors_3751223.png",
        "date": "2025-12-08 11:00:57",
        "description": "Godavari Drugs has reached a new 52-week low of Rs.70.31 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year."
      },
      {
        "title": "Godavari Drugs Stock Falls to 52-Week Low of Rs.70.31 Amidst Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-stock-hits-52-week-low-amidst-continued-downtrend-3751222",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GodavariDrugs_priceRelatedfactors_3751222.png",
        "date": "2025-12-08 11:00:37",
        "description": "Godavari Drugs has reached a new 52-week low of Rs.70.31, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year."
      }
    ],
    "total": 156,
    "sid": "765253",
    "stock_news_url": "https://www.marketsmojo.com/news/godavari-drugs-765253"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ending On December 31 2025.",
      "datetime": "07-Feb-2026",
      "details": "Godavari Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ending on December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "CORRIGENDUM IN CONTINUATION TO THE NOTICE AND EXPLANATORY STATEMENT ATTACHED THERETO DATED 15.01.2026 CONVENING THE 01St EXTRA ORDINARY GENERAL MEETING FOR FY 2025-26 OF GODAVARI DRUGS LIMITED TO BE HELD ON THURSDAY 12.02.2026 AT 11:00 A.M.",
      "datetime": "02-Feb-2026",
      "details": "CORRIGENDUM TO EGM TO BE HELD ON 12.02.2026",
      "source": "BSE"
    },
    {
      "caption": "EXTRA-ORDINARY GENERAL MEETING WILL BE HELD ON THURSDAY THE 12TH DAY OF FEBRUARY 2026 AT 11:00 A.M. THROUGH VIDEO CONFERENCING AND OTHER AUDIO-VISUAL MEANS",
      "datetime": "21-Jan-2026",
      "details": "EGM will be held on 12.02.2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Godavari Drugs Ltd latest results good or bad?

2026-02-11 19:30:17

The latest financial results for Godavari Drugs Ltd for the quarter ending September 2025 reflect a complex operational landscape. The company reported net sales of ₹26.65 crores, which represents a sequential growth of 11.93% compared to the previous quarter's ₹23.81 crores. However, year-on-year growth is modest at just 2.15%, indicating that while there is some recovery in sales, it is not keeping pace with broader market expectations. In terms of profitability, net profit for the quarter was ₹1.00 crore, reflecting a decline of 3.85% from the previous quarter and an 8.26% decrease year-on-year. This decline in profit is concerning, especially as it coincides with a significant drop in operating margins, which fell to 7.47%, the lowest level recorded in the past seven quarters. This margin compression is indicative of ongoing challenges, including rising input costs and pricing pressures in the active p...

Read full news article

Godavari Drugs Ltd is Rated Strong Sell

2026-02-10 10:10:07

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Godavari Drugs Ltd is Rated Strong Sell

2026-01-30 10:10:03

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Godavari Drugs Ltd is Rated Strong Sell

2026-01-19 10:10:32

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Godavari Drugs Ltd is Rated Strong Sell

2026-01-07 10:10:23

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics presented here are based on the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and prospects.

Read full news article

Godavari Drugs Ltd is Rated Strong Sell

2025-12-25 15:12:53

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and prospects.

Read full news article

Godavari Drugs Stock Hits 52-Week Low at Rs.69.7 Amidst Prolonged Downtrend

2025-12-09 11:23:32

Godavari Drugs has reached a new 52-week low of Rs.69.7, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.

Read full news article

Godavari Drugs Stock Falls to 52-Week Low of Rs.70.31 Amidst Continued Downtrend

2025-12-08 11:00:57

Godavari Drugs has reached a new 52-week low of Rs.70.31 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Read full news article

Godavari Drugs Stock Falls to 52-Week Low of Rs.70.31 Amidst Prolonged Downtrend

2025-12-08 11:00:37

Godavari Drugs has reached a new 52-week low of Rs.70.31, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Read full news article

View All News